30-11-2022
Aker BioMarine submits research application – aims to shed light on new raw materials for aquafeed through new research
In partnership with LetSea and Nofima, Aker BioMarine submitted its application to the Norwegian Directorate of Fisheries to...
11-11-2022
Aker BioMarine introduces a new delivery platform for enhanced bioavailability of dietary supplement ingredients
This new disruptive technology platform, utilizing the true potential of phospholipids (PL’s), will help bring new products...
08-11-2022
Aker BioMarine signs 18 strategic partnership agreements at China International Import Expo
Oslo, November 8, 2022: Aker BioMarine is onsite in Shanghai at China International Import Expo (CIIE) from November 5-10,...
08-09-2022
Aker BioMarine strengthens QRILL™ Aqua sales team with new talent
(Oslo, September 6, 2022) Aker BioMarine is enhancing its QRILL™ Aqua sales organization after successfully recruiting two...
06-09-2022
Aker BioMarine, CSIRO and Swisse winners of the 2022 Nutra Ingredients Asia Award
(Tuesday, September 6th, 2022) Aker BioMarine, CSIRO and Swisse took home this year’s Nutrition Research Project prize at...
01-09-2022
First commercial agreement signed for Lysoveta
Oslo, 1 September 2022: Reference is made to the stock exchange release on 11 January 2021, with the announcement of the...
31-08-2022
Aker BioMarine’s Patent Portfolio is Strengthened in the United States
(August 31, 2022) The United States Patent Trial and Appeal Board (PTAB) has rejected a challenge against Aker BioMarine’s...
28-07-2022
Breakthrough study demonstrates positive effects of krill oil to improve osteoarthritis of the knee
Oslo, July, 27, 2022: A new study conducted by CSIRO, Australia’s national science agency, across three clinical trial sites...
14-07-2022
Aker BioMarine - second quarter 2022
14 July 2022: Aker BioMarine ASA (“Aker BioMarine” or “the company”) reports revenues of USD 73 million and Adjusted EBITDA...